X4 Pharmaceuticals Inc (XFOR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $318.59M
Last updated: Nov 17, 2026 at 11:05 AM ET
X4 Pharmaceuticals Inc (XFOR) Stock Forecast
Analysts expect X4 Pharmaceuticals (XFOR) to earn -$0.64 per share in the fiscal year ending Dec 31, 2026, on revenue of $17.17M. Of 5 analysts, 5 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 5 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 32.2%.
- Fiscal year ending Dec 31, 2026
- -$0.64
- EPS consensus, revenue $17.17M
- Fiscal year ending Dec 31, 2027
- -$0.77
- EPS consensus, revenue $11.64M
- Next report
- Mar 15, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.64 | -$0.69 to -$0.62 | 3 | $17.17M | $16.90M to $17.70M | 3 |
| Dec 31, 2027 | -$0.77 | -$1.00 to -$0.65 | 4 | $11.64M | $6.50M to $17.70M | 5 |
Quarterly Estimates
The EPS consensus rises from -$0.20 for the quarter ending Dec 31, 2026 to -$0.19 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.20 | -$0.27 to -$0.17 | 7 | $2.81M | $2.45M to $3.46M | 7 |
| Mar 31, 2027 | -$0.19 | -$0.19 to -$0.19 | 2 | $2.20M | $2.00M to $2.40M | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.69.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.64 | -$0.67 | -$0.67 | -$0.67 | -$0.69 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.77 | -$0.77 | -$0.77 | -$0.76 | -$0.79 | N/A |
| Quarter ending Mar 31, 2027 | -$0.19 | -$0.19 | -$0.19 | -$0.19 | -$0.19 | N/A |
Frequently Asked Questions About XFOR
What is the XFOR stock forecast?
Consensus analyst estimates put X4 Pharmaceuticals's EPS at -$0.64 for the fiscal year ending Dec 31, 2026, on revenue of $17.17M. The consensus rating from 5 analysts is Buy.
How do analysts rate XFOR stock?
Of 5 analysts covering X4 Pharmaceuticals, 0 rate it Strong Buy, 5 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from XFOR next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.64, with estimates from -$0.69 to -$0.62 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.77, with estimates from -$1.00 to -$0.65 from 4 analysts.
What revenue do analysts expect from X4 Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $17.17M, with estimates from $16.90M to $17.70M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $11.64M, with estimates from $6.50M to $17.70M.
How many analysts cover XFOR?
5 analysts rate X4 Pharmaceuticals stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
XFOR pages: Overview, Earnings, Forecast, Financials, Competitors